GeoVax Labs Inc
NASDAQ:GOVX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (15.8), the stock would be worth $27.28 (2 231% upside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.7 | $1.17 |
0%
|
| 3-Year Average | 15.8 | $27.28 |
+2 231%
|
| 5-Year Average | 26.7 | $45.96 |
+3 829%
|
| Industry Average | 4.6 | $7.89 |
+574%
|
| Country Average | 2.5 | $4.33 |
+270%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
GeoVax Labs Inc
NASDAQ:GOVX
|
2.6m USD | 0.7 | -0.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -164 720.7 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
354.5B USD | -108.4 | 84.7 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
186.5B USD | 21.5 | 24.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
164.9B USD | 7.3 | 19.4 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -5 465.3 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
111.2B USD | 6 | 28.1 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.9B USD | 2.5 | 17.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42B EUR | 6.7 | 37.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.3B AUD | 2.3 | 30.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 18.2 | -61.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.5 |
| 70th Percentile | 4.8 |
| Max | 147 580.5 |
Other Multiples
GeoVax Labs Inc
Glance View
GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of immunotherapies and vaccines against cancers and infectious diseases using a novel vector vaccine platform. The company is headquartered in Smyrna, Georgia. The firm is focused on developing human vaccines and immunotherapies against infectious diseases and cancer using its platforms. Its product pipeline includes ongoing human clinical trials for COVID-19 and head and neck cancer. The firm is developing a number of vaccines and immunotherapies for prevention or treatment of infectious diseases and cancers. The Company’s product candidate includes GEO-CM04S1, GEO-CM02, Gedeptin, MVA-VLP-MUC1, GEO-ZM02, GEO-EM01, GEO-LM01 and GEO-MM02. Its research and development programs include preventive vaccines against Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa) and malaria, as well as immunotherapies for multiple solid tumors. The Company’s wholly owned subsidiaries include GeoVax, Inc. and Immutak Oncology, Inc.
